90 related articles for article (PubMed ID: 16142999)
1. Sarcomas and pharmacogenetics.
Biason P; Toffoli G
Pharmacogenomics; 2005 Sep; 6(6):585-601. PubMed ID: 16142999
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
Hartmann JT; Patel S
Drugs; 2005; 65(2):167-78. PubMed ID: 15631540
[TBL] [Abstract][Full Text] [Related]
3. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
Gelderblom H; Blay JY; Seddon BM; Leahy M; Ray-Coquard I; Sleijfer S; Kerst JM; Rutkowski P; Bauer S; Ouali M; Marreaud S; van der Straaten RJ; Guchelaar HJ; Weitman SD; Hogendoorn PC; Hohenberger P
Eur J Cancer; 2014 Jan; 50(2):388-96. PubMed ID: 24215845
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Hartmann JT
Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
[TBL] [Abstract][Full Text] [Related]
7. Appraising the current role of chemotherapy for the treatment of sarcoma.
D'Adamo DR
Semin Oncol; 2011 Oct; 38 Suppl 3():S19-29. PubMed ID: 22055968
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy of soft tissue sarcomas.
Wardelmann E; Chemnitz JM; Wendtner CM
Onkologie; 2012; 35 Suppl 1():21-7. PubMed ID: 22286584
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and folate metabolism -- a promising direction.
Ulrich CM; Robien K; Sparks R
Pharmacogenomics; 2002 May; 3(3):299-313. PubMed ID: 12052139
[TBL] [Abstract][Full Text] [Related]
10. Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery.
Aragon-Ching JB; Maki RG
Cancer Invest; 2012 May; 30(4):300-8. PubMed ID: 22480231
[TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
12. Role of chemotherapy in patients with soft tissue sarcomas.
Maki RG
Expert Rev Anticancer Ther; 2004 Apr; 4(2):229-36. PubMed ID: 15056053
[TBL] [Abstract][Full Text] [Related]
13. A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib.
Alavi SN; Florou V; Tinoco G; Trent JC; Wilky BA
Discov Med; 2018 Mar; 25(137):131-144. PubMed ID: 29641974
[TBL] [Abstract][Full Text] [Related]
14. Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004.
Fayette J; Blay JY
Curr Opin Oncol; 2005 Jul; 17(4):370-5. PubMed ID: 15933471
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology and potential therapeutic targets in soft-tissue sarcoma.
Todd R; Lunec J
Expert Rev Anticancer Ther; 2008 Jun; 8(6):939-48. PubMed ID: 18533803
[TBL] [Abstract][Full Text] [Related]
17. Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
Kasper B; Ho AD; Egerer G
Oncology; 2005; 68(2-3):115-21. PubMed ID: 15886503
[TBL] [Abstract][Full Text] [Related]
18. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
19. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment.
Shimoyama S
J Gastroenterol Hepatol; 2009 Jun; 24(6):970-81. PubMed ID: 19638079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
